TY - JOUR
T1 - Contemporary Issues in Chronic Total Occlusion Percutaneous Coronary Intervention
AU - Azzalini, Lorenzo
AU - Karmpaliotis, Dimitri
AU - Santiago, Ricardo
AU - Mashayekhi, Kambis
AU - Di Mario, Carlo
AU - Rinfret, Stéphane
AU - Nicholson, William J.
AU - Carlino, Mauro
AU - Yamane, Masahisa
AU - Tsuchikane, Etsuo
AU - Brilakis, Emmanouil S.
N1 - Funding Information:
Dr Azzalini has received honoraria from Teleflex, Abiomed, Asahi Intecc, Philips, Abbott Vascular, and Cardiovascular Systems, Inc. Dr Karmpaliotis has received honoraria from Boston Scientific and Abbott Vascular; and has equity in Saranas, Traverse Vascular, and Soundbite. Dr Santiago has received speaker and proctoring honoraria from Boston Scientific, Abbott Vascular, and Teleflex. Dr Mashayekhi has received consulting, speaker, and proctoring honoraria from Abbott Vascular, Ashai Intecc, AstraZeneca, Biotronik, Boston Scientific, Cardinal Health, Daiichi-Sankyo, Medtronic, Teleflex, and Terumo. Dr Di Mario has received research grants from Amgen, Behring, Boston Scientific, Chiesi, Daiichi-Sankyo, Edwards Lifesciences, Medtronic, Shockwave Medical, and Volcano/Philips. Dr Rinfret has received consulting honoraria from Boston Scientific, Teleflex, Abbott Vascular, Medtronic, and Soundbite Medical. Dr Nicholson has received proctoring and advisory board honoraria from Abbott Vascular, Boston Scientific, Medtronic, and Asahi Intecc. Dr Tsuchikane has received consulting honoraria from Asahi Intecc, Kaneka, Nipro, and Boston Scientific. Dr Brilakis has received consulting and speaker honoraria from Abbott Vascular, the American Heart Association (associate editor, Circulation), Amgen, Asahi Intecc, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, Cardiovascular Systems, Inc, Elsevier, GE Healthcare, IMDS, InfraRedx, Medicure, Medtronic, Opsens, Siemens, and Teleflex; is an owner of Hippocrates; and is a shareholder in MHI Ventures and Cleerly Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/1/10
Y1 - 2022/1/10
N2 - Remarkable progress has been achieved in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in recent years, with refinement of the indications and technical aspects of the procedure, imaging, and complication management. Randomized controlled trials and rigorous prospective registries have provided high-quality data on the benefits and risks of CTO PCI. Global collaboration has led to an agreement on nomenclature, indications, endpoint definition, and principles of clinical trial design that have been distilled in global consensus documents such as the CTO Academic Research Consortium. Increased use of preprocedural coronary computed tomography angiography and intraprocedural intravascular imaging, as well as development of novel techniques and structured CTO crossing and complication management algorithms, allow a systematic, stepwise approach to this difficult lesion subset. This state-of-the-art review provides a comprehensive discussion about the most recent developments in the indications, preprocedural planning, technical aspects, complication management, and future directions of CTO PCI.
AB - Remarkable progress has been achieved in chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in recent years, with refinement of the indications and technical aspects of the procedure, imaging, and complication management. Randomized controlled trials and rigorous prospective registries have provided high-quality data on the benefits and risks of CTO PCI. Global collaboration has led to an agreement on nomenclature, indications, endpoint definition, and principles of clinical trial design that have been distilled in global consensus documents such as the CTO Academic Research Consortium. Increased use of preprocedural coronary computed tomography angiography and intraprocedural intravascular imaging, as well as development of novel techniques and structured CTO crossing and complication management algorithms, allow a systematic, stepwise approach to this difficult lesion subset. This state-of-the-art review provides a comprehensive discussion about the most recent developments in the indications, preprocedural planning, technical aspects, complication management, and future directions of CTO PCI.
KW - CTO
KW - coronary chronic total occlusion
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=85121608614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121608614&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2021.09.027
DO - 10.1016/j.jcin.2021.09.027
M3 - Review article
C2 - 34991814
AN - SCOPUS:85121608614
SN - 1936-8798
VL - 15
SP - 1
EP - 21
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 1
ER -